Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study
Authors
Keywords
-
Journal
Targeted Oncology
Volume 17, Issue 4, Pages 467-474
Publisher
Springer Science and Business Media LLC
Online
2022-06-25
DOI
10.1007/s11523-022-00892-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
- (2021) Chun Loo Gan et al. Cancer Medicine
- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2021) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real‐World Evidence in Oncology: Opportunities and Limitations
- (2020) Massimo Di Maio et al. ONCOLOGIST
- Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma
- (2020) Nityam Rathi et al. Cancer Management and Research
- Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma
- (2020) Praful Ravi et al. JAMA Oncology
- Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial
- (2020) Robert J. Motzer et al. CANCER
- Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis
- (2020) Roberto Iacovelli et al. Targeted Oncology
- Real World Data of Nivolumab for Advanced Renal-Cell Carcinoma Patients in the Netherlands: An analysis of toxicity, efficacy and predictive markers
- (2020) Saskia Lisa Verhaart et al. Clinical Genitourinary Cancer
- Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
- (2020) Thomas Powles et al. LANCET ONCOLOGY
- Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program
- (2020) Laurence Albiges et al. EUROPEAN JOURNAL OF CANCER
- Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
- (2019) Elena Verzoni et al. Journal for ImmunoTherapy of Cancer
- Surgical Safety of Cytoreductive Nephrectomy Following Systemic Therapy: What Should We Look For?
- (2019) Umberto Capitanio et al. EUROPEAN UROLOGY
- Treatment sequences for advanced renal cell carcinoma: A health economic assessment
- (2019) Baris Deniz et al. PLoS One
- Effect of third- and fourth-line systemic therapies for metastatic renal cell carcinoma
- (2019) Sei Naito et al. Scientific Reports
- Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
- (2019) Matteo Santoni et al. Cancers
- Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma
- (2018) Robert J. Motzer et al. BRITISH JOURNAL OF CANCER
- The use of real-world data in cancer drug development
- (2018) E. Skovlund et al. EUROPEAN JOURNAL OF CANCER
- Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation
- (2018) Steve J Edwards et al. HEALTH TECHNOLOGY ASSESSMENT
- Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data
- (2018) Nicholas J. Vogelzang et al. Journal of Managed Care & Specialty Pharmacy
- Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China
- (2018) Guohai Shi et al. JOURNAL OF MEDICAL ECONOMICS
- Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
- (2017) J. Connor Wells et al. EUROPEAN UROLOGY
- Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges
- (2016) Francesca Tartari et al. CANCER TREATMENT REVIEWS
- Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma
- (2016) Marco Maruzzo et al. Future Oncology
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy
- (2015) Matteo Santoni et al. Targeted Oncology
- Prognostic role of the neutrophil-lymphocyte ratio in renal cell carcinoma: a meta-analysis
- (2015) K. Hu et al. BMJ Open
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
- (2013) Daniel YC Heng et al. LANCET ONCOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
- (2011) Razelle Kurzrock et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Epidemiology, Clinical Staging, and Presentation of Renal Cell Carcinoma
- (2008) G. Joel DeCastro et al. UROLOGIC CLINICS OF NORTH AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search